Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes

OBJECTIVE:--To determine the prevalence of painful diabetic peripheral neuropathy (PDPN) in a population-based sample and to estimate its severity and impact. RESEARCH DESIGN AND METHODS--A cross-sectional descriptive study consisting of two phases: phase 1, a postal survey to patients with type 2 d...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes care Ročník 29; číslo 7; s. 1518 - 1522
Hlavní autoři: Davies, Mark, Brophy, Sinead, Williams, Rhys, Taylor, Ann
Médium: Journal Article
Jazyk:angličtina
Vydáno: Alexandria, VA American Diabetes Association 01.07.2006
Témata:
Aged
Associated diseases and complications
Biological and medical sciences
Care and treatment
Causes of
complications
Cross-Sectional Studies
descriptive studies
Diabetes
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2 - complications
Diabetes. Impaired glucose tolerance
Diabetic Nephropathies
Diabetic Nephropathies - epidemiology
Diabetic neuropathy
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
epidemiology
etiology
Female
Health services
Humans
Male
Measurement errors
Medical sciences
Middle Aged
noninsulin-dependent diabetes mellitus
pain
Pain - epidemiology
Pain - etiology
patients
Peripheral nerve diseases
peripheral nervous system diseases
Prevalence
Primary care
Quality of Life
questionnaires
risk
Risk factors
screening
surveys
Type 2 diabetes
Wales
Wales - epidemiology
Wales
United States
Endocrinopathy
Type 2 diabetes
Human
Nervous system diseases
Pain
Prevalence
Metabolic diseases
Complication
Peripheral nerve disease
Peripheral neuropathy
Quality of life
ISSN:0149-5992, 1935-5548
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:OBJECTIVE:--To determine the prevalence of painful diabetic peripheral neuropathy (PDPN) in a population-based sample and to estimate its severity and impact. RESEARCH DESIGN AND METHODS--A cross-sectional descriptive study consisting of two phases: phase 1, a postal survey to patients with type 2 diabetes (an initial screening questionnaire including one question about pain); phase 2, neurological history and examination using the Toronto Clinical Scoring System. Subjects with PDPN or mixed (PDPN and nonneuropathic) pain completed the Neuropathic Pain Scale and Neuroqol to assess severity and nature of the pain and impact on quality of life. Those without PDPN completed the Neuroqol only. RESULTS:--In phase 1, there was a 92.7% response (n = 326), with 208 (63.8%) subjects reporting pain. In phase 2, 269 (82.5%) subjects attended and 51 (19.0%) were found to have PDPN: 99 (36.8%) nonneuropathic pain, 20 (7.4%) mixed pain, and 99 (36.8%) no pain (PDPN prevalence 26.4%). Of those with PDPN, 80% stated that their pain was moderate or severe. Those affected had poorer quality of life than those with no pain (difference in mean scores 3.6 [95% CI 2.5-4.6%]) compared with those with nonneuropathic pain (1.7 [0.4-2.9%]). Both pain and neuropathy score were independently associated with quality of life, and subjects with PDPN had significantly higher neuropathy scores. CONCLUSIONS:--Our study showed a prevalence of PDPN of 26.4%. Having PDPN has a significant negative effect on quality of life, and increasing neuropathy is associated with an increasing risk of developing PDPN.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0149-5992
1935-5548
DOI:10.2337/dc05-2228